Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCTBiotechnology
+$0.15 today
- Market cap
- $229.72M
- Beta
- 2.35
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$2.77
Volume 0.45M
Average 0.43M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCT
Intrinsic Alpha fair value
Locked
Current Price
$7.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | -31.1% | +37.7% (5yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Recent growth has been strongest in Revenue at -31.1% over three years. Forward estimates point to Revenue at +37.7% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Vir Biotechnology, Inc. NASDAQ:VIR | $1.71B | $9.96 | Not rated | -3.0 | +68.18% |
Novavax, Inc. NASDAQ:NVAX | $1.41B | $8.53 | Not rated | -17.3 | +21.16% |
Silence Therapeutics plc NASDAQ:SLN | $936.65M | $19.83 | Not rated | -3.9 | +193.33% |
Arbutus Biopharma Corporation NASDAQ:ABUS | $810.25M | $4.09 | Not rated | 5.4 | -8.99% |
Valneva SE NASDAQ:VALN | $538.42M | $5.66 | Not rated | -2.9 | -36.69% |
Atea Pharmaceuticals, Inc. NASDAQ:AVIR | $345.31M | $4.30 | Not rated | -2.0 | +29.84% |
Benitec Biopharma Inc. NASDAQ:BNTC | $315.40M | $9.04 | Not rated | -12.3 | -39.76% |
Rocket Pharmaceuticals, Inc. NASDAQ:RCKT | $252.48M | $2.30 | Not rated | -1.7 | -28.23% |
ProQR Therapeutics N.V. NASDAQ:PRQR | $198.98M | $1.41 | Not rated | -3.8 | -44.71% |
Inovio Pharmaceuticals, Inc. NASDAQ:INO | $98.80M | $1.43 | Not rated | -8.9 | -13.76% |
Continue the stock analysis
Jump to another research area for this company.